Galectin Therapeutics (GALT) Research & Development (2010 - 2026)
Galectin Therapeutics' quarterly Research & Development came in at $2.2 million in Q1 2026, down 65.6% year-on-year from $6.5 million in Q1 2025, and up 15.42% quarter-over-quarter from $1.9 million in Q4 2025.
Galectin Therapeutics has reported Research & Development for 17 years, with the latest figure at $2.2 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 65.6% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.0 million (down 71.33% YoY), and the FY2025 full-year result was $14.3 million, down 60.93% from the prior year.
- Research & Development for Q1 2026 stood at $2.2 million, up from $1.9 million in the prior quarter.
- The five-year high for Research & Development was $11.1 million in Q4 2024, with the low at $1.9 million in Q4 2025.
- Average Research & Development over 5 years is $6.9 million, with a median of $7.7 million recorded in 2023.
- Year-over-year, Research & Development soared 64.48% in 2022 and sank 82.6% in 2025.
- Tracing GALT's Research & Development over 5 years: stood at $9.0 million in 2022, then declined by 8.65% to $8.2 million in 2023, then surged by 35.01% to $11.1 million in 2024, then slumped by 82.6% to $1.9 million in 2025, then climbed by 15.42% to $2.2 million in 2026.
- The last three Research & Development figures came in at $2.2 million (Q1 2026), $1.9 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 1.93 Mn |
| Sep 30, 2025 | 2.61 Mn |
| Jun 30, 2025 | 3.26 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 11.11 Mn |
| Sep 30, 2024 | 7.60 Mn |
| Jun 30, 2024 | 9.81 Mn |
| Mar 31, 2024 | 8.05 Mn |
| Dec 31, 2023 | 8.23 Mn |
| Sep 30, 2023 | 7.73 Mn |
| Jun 30, 2023 | 7.37 Mn |
| Mar 31, 2023 | 8.80 Mn |
| Dec 31, 2022 | 9.01 Mn |
| Sep 30, 2022 | 6.60 Mn |
| Jun 30, 2022 | 8.07 Mn |
| Mar 31, 2022 | 8.06 Mn |
| Dec 31, 2021 | 5.86 Mn |
| Sep 30, 2021 | 6.61 Mn |
| Jun 30, 2021 | 6.45 Mn |
| Mar 31, 2021 | 4.90 Mn |
| Dec 31, 2020 | 6.37 Mn |
| Sep 30, 2020 | 4.78 Mn |
| Jun 30, 2020 | 4.68 Mn |
| Mar 31, 2020 | 2.14 Mn |
| Dec 31, 2019 | 3.80 Mn |
| Sep 30, 2019 | 1.50 Mn |
| Jun 30, 2019 | 1.52 Mn |
| Mar 31, 2019 | 646,000.00 |
| Dec 31, 2018 | 1.19 Mn |
| Sep 30, 2018 | 1.51 Mn |
| Jun 30, 2018 | 1.48 Mn |
| Mar 31, 2018 | 2.30 Mn |
| Dec 31, 2017 | 1.00 Mn |
| Sep 30, 2017 | 3.50 Mn |
| Jun 30, 2017 | 3.44 Mn |
| Mar 31, 2017 | 3.77 Mn |
| Dec 31, 2016 | 3.43 Mn |
| Sep 30, 2016 | 3.29 Mn |
| Jun 30, 2016 | 4.23 Mn |
| Mar 31, 2016 | 4.38 Mn |
| Dec 31, 2015 | 2.91 Mn |
| Sep 30, 2015 | 4.46 Mn |
| Jun 30, 2015 | 2.60 Mn |
| Mar 31, 2015 | 3.14 Mn |
| Dec 31, 2014 | 2.08 Mn |
| Sep 30, 2014 | 1.98 Mn |
| Jun 30, 2014 | 1.59 Mn |
| Mar 31, 2014 | 2.77 Mn |
| Dec 31, 2013 | 1.40 Mn |
| Sep 30, 2013 | 1.19 Mn |
| Jun 30, 2013 | 1.35 Mn |
| Mar 31, 2013 | 1.75 Mn |
| Dec 31, 2012 | 1.00 Mn |
| Sep 30, 2012 | 1.41 Mn |
| Jun 30, 2012 | 1.22 Mn |
| Mar 31, 2012 | 901,000.00 |
| Dec 31, 2011 | 862,000.00 |
| Sep 30, 2011 | 655,000.00 |
| Jun 30, 2011 | 1.29 Mn |
| Mar 31, 2011 | 744,000.00 |
| Dec 31, 2010 | 390,000.00 |
| Sep 30, 2010 | 313,000.00 |
| Jun 30, 2010 | 234,000.00 |